have also been included. However, selected cases have been subjecti to these expensive and invasive tests. Moreover, definition of 'chest failure' commonly includes distant chest sitescontralateral lung, ipsilateral, parenchymal, and pleural-based densities or effusions. Furthermore, in patients failing at distant sites, attention to local control or failure was likely to be less carefully detailed. Separating the evaluation of failure pattern into 'lung only' and 'local plus distant', if accurate, focuses on whether better local treatment or better systemic treatment is more important. Those with systemic failure have no prospect for improvement with local modalities.
Local failure data commonly report failure fmm response. It is not clear how patients with less-than complete response are handled. When treatment regimens have varied response rates, the proportion failing initial treatment and the proportion that fail after initial response are quite different. The term 'local control' is applied to all patients, but 'local failure' is commonly applied only after failure from response, but these terms are not used uniformly. Furthermore, studies with short median survival or few 2-year survivors may overestimate local control. Determination of local status can be quite subjective in patients receiving TRT. Thus, future trials need to study the endpoint of local control recognizing the above pitfalls and then design studies that can clarify these issues.
If the issue of excessive local failure is important, optimizing TRT may yield results. Defining (1) volume, (2) course, (3) dose, (4) duration of therapy, as well as integration with systemic therapy are all issues that have received surprisingly little attention. These variables certainly may influence local control and possibly survival. Table 1 presents the local control reported from 10 recent studies.
These studies were selected because they reported local failure or control. In the 4 contmlled studies, TRT reduced local failure on each study. With CC alone local failure ranged between 40% and 82%; with the addition of TRT it ranged between 18% and 69%.
Volume, course, dose Prechemotherapy vs post-chemotherapy TRT volume is a topic of discussion in other diseases. For concurrent methods, the initial volume is the pre-chemotherapy volume. With the alternating strategy, the subsequent courses can often have reduced volumes, but no study reports the influence of either maintaining a large volume or reducing it after response. The sequential method is the setting to evaluate this. Using larger volumes versus smaller or tighter volumes is another issue. Understanding the physics of field borders and the lymphatic spread of lung mmors has caused TRT field sires to increase. Radiating larger field sixes necessarily increases dose to normal tissues, which potentially increases toxicity, particularly in conjunction with CC. Table 2 demonstrates the influence of larger versus smaller volumes as described in these studies. Custom shields or blocks and techniques to maximize tumor dose and minimize normal tissue dose warrant attention. Posterior spinal shields inadvertently protect the mediastinum, and this may cause local failure. The merit or folly of larger field sixes is unknown.
Continuous course is thought to be better than split-course because it prevents the regrowth of surviving tumor cells between courses. Very few facts bolsters this theory. The alternating strategy requires split-courses. However, effective chemotherapy may prevent or inhibit proliferation of tumor cells between courses.
Dose can be quite difficult to sort out because the biological equivalent dose of different fractionation schemes is poorly expressed in rad. Gray (Gy) or other physical units. The effects on acme-effect tissue (tumors, bone marrow, mucosa) may not be paralleled in late-effect time (brain, lung). NSD and cr&ratio models need further testing. The influence of time and chemotherapy on these variables may be quite important, but arc presently poorly understood. As a general rule, fraction sizes greater than 2 Gy are more harmful to late-effect tissue, but kill more acute tissue per session. Conversely, fraction sire less than 2 Gy respect late tissue, but kill fewer acute effect tissues per session. Simply comparing total doses amongst reported studies can be quite misleading. With this in mind, Table 3 describes the reported failure by total dose. V--varied -most cyclophosphatnide-based, some used platin~-baskd; A=platinum-based; B=cyclophosphamide-based.
Y?nd randomization for responders to: ItA. Highlighted studies Choi retrospectively analyzed 207 patients from the Massachusetts General Hospital between 1974 and 1977 1101. The TRT dose ranged from 30 to 40 Gy in the early years, and after 1978 the TRT dose increased from 44 to 52 Gy. Doses of 30 and 35 Gy had a failure of 100% and 79%, respectively. The TRT doses between 45 and 50 Gy had local failure of 39% and 36%. respectively. The dose 40 Gy has a local failure of 43%. The authors suggested that these data show a 'dose-response' relationship. Details regarding volume, pre-or post-CC, total time of ueatment and method of integration of TRT and CC were not discussed. These data were collected over a decade, with changes in staging, CC and dose, but the univariate analysis evaluated dose only. Local failure does not seem to improve appreciably above 40 Gy.
Sequential trials
Yale 1111 used cytoxan, etoposide and methotrexate, an infrequently used CC regimen, for 3 cycles followed by splitcourse TRT (60 Gy/6 weeks/3 Gy/fraction). The local failure was only 3.8%. However, 42% had less than CR, %-year survival was ~30%. Duration of follow-up (minimum or median) was not mentioned. Only 7/26 patients remained alive. We know one local failure (? from CR), but status of the other 25 patients remains in doubt, and durability of the local control in the 7 survivors mmains in question. TRT volume, pre-or post-chemotherapy, use of spinal cord blocks, and methods of assessment of local control were not discussed. Furthermore, ultimate local control, as opposed to first failure, would be noteworthy.
The Memorial Sloan-Kettering developed the PE regimen, alternated it with CAV, prior to 45 Gy continuous course, 4 days/week using 2.5 Gy fractions. The target volumes were determined by CT scan, using multiple-field techniques (3 fields, some laterals). Whether volumes were pre-or post-chemotherapy was not reported. Of 34 patients, 12 achieved CR (35%) and 18 achieved PR (53%) after CC, and increased to 65% CR and 26% PR after TRT. Four failed infield, 3 outside the field and 2 both. Local failure was 292, and local control was 65% (22/34). However. there were 9 local failures, but it is not clear what denominator is appropriate. Since the initial CR rate to chemotherapy was only 35% and 65% after TRT, longer follow-up may have yielded more locoregional failures, but that data was not provided. Alternating schemes The first SEG and the Institute Gustave Roussy (IGR) both used CC on week 1 of cycles followed by large fraction (2.5-3.0 Gy), split-course TRT to total doses of 40 Gy (weeks 58 and 11) for the SEG trial and 45-55 Gy (weeks 6. 12, 15) for the IGR. The SEG trial was randomized, the CC group failed in 42% but the TRT group failed in 23%. The IGR reported 12% failure in the chest alone, but 25% in chest plus other sites. The technical factors were not discussed by the SEG, but the IGR did boost off cord for 15 Gy with lateral or angled fields.
Concurrent trials
The second SEG, Cancer and Leukemia Group B (CALGB), and National Cancer Institute @ICI) all used cyclophosphamide-based CC and concurrent TRT. The NC1 and CALGB used continuous courts for 3 and 5 weeks, respectively, but the SEG used split-course with TRT administered in 3 Gy fractions during weeks 1,2 and 4. The NC1 used 40 Gy in 3 weeks (2.66 Gy/fraction) and wide posterior spinal cord shields. Failure in the chest was recorded at 67% for the CC group versus 29% for the TRT group. Variant histology was excluded from the NC1 trial. The CALGB used 50 Gy in 5 weeks (2.0 Gy/fraction), using a large volume technique, which included the entire mediastinum plus the supraclavicular fossa. There were 3 arms: (1) immediate TRT; (2) delayed TRT, and (3) not TRT. The chest-only and chest plus distant metastasis (DM) was: (1) 28% and 37%; (2) 42% and 69%; and (3) 67% and 82%. The concurrent SEG trial used 45 Gy during the first two CAV cycles. The addition of TRT did not improve survival. A subsequent randomization to PE improved survival in those randomized. The local failure of this trial was 40% in the CC group versus 18% in arms randomized to TRT. A retrospective comparison between the SEG alternating and concurrent trials showed a local and DM of 22% versus 35%. respectively, P=O.Ol; however, there was no difference for local only [ 121;
Concurrent PE and TRT
The Southwest Oncology Group (SWGG) and University of Pennsylvania (Penn) have both used PE regimens (not identical) and 45 Gy TRT. The SWGG gave 45 Gy in 5 weeks. The SWGG trial used generous fields with 2-2.5 cm margins including the entire mediastinum, contralateral hilum and both supraclavicular fossae. The off-cord technique is not described. Penn gave 45 Gy in 3 weeks using 1.5 Gy fractions Bid, CT planning and avoiding direct posteriorspinal cord blocks. Penn's fields were 'tight' with a margin of 1.0-1.5 cm. Average field size was 13.5x16.5 (range 11-17.5 cm x 12-26.5 cm). The contralateral hilum was never treated. Only 45% had ipsilateral supraclavicular fossa treated. The SWGG will report on 154 patients with 12% chest or chest and brain failure, but 26 less than PR patients (17%) are not scored as failures. The Penn trial had only 2/31 (6%) with less than CR. With a median follow-up of 42 months, 5/31 (16%) have failed locally. All had variant histology (415 presented with variant histology). For pure SCLC, the total failure was 4% (l/27), and zero for those receiving full dose TRT.
In conclusion, studies vary in how they report local control and failure. Although multiple variables may be important, most authors isolate variables chosen for discussion. No convincing data points to a dose-response relationship above 40 Gy. The issue of sequence and type of CC are linked to this issue; definitively for toxicity, but probably response too. There are no studies addressing pre-versus postchemotherapy volume or large volume vs small volume. Technique of lung and spinal cord protection influence results, but no study specifically addressed this issue. The larger volume, larger dose, larger margin studies do not appear to have better survival or local control than the small study, which intentionally avoids the supraclavicular and contralateral hilar nodes.
These issues would probably not warrant a prospective trial, but carefully designed trials can identify these factors and report their influence.
